A review of the use of trastuzumab (Herceptin®) plus vinorelbine in metastatic breast cancer

Annals of Oncology

Volumn 18, Issue 7, 2007, Pages 1152-1158

  Chan, Arlene ^a  

^a Mount Hospital   (Australia)

Author keywords

Adverse effects; Breast neoplasms; Combination drug therapy; Trastuzumab; Treatment outcome; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ACUTE HEART INFARCTION; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; INFECTION; INJECTION SITE REACTION; KIDNEY FAILURE; LEUKOPENIA; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PHLEBITIS; PRIORITY JOURNAL; REVIEW; SENSORY DYSFUNCTION; SEPSIS; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VEIN DISEASE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; VINBLASTINE;

EID: 33947692030     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl476     Document Type: Review

References (30)

1. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
2. Bilous M, Dowsett M, Hanna W et al. Current perspectives on HER2 testing: A review of national testing guidelines. Mod Pathol 2003; 16: 173-182.
3. Bast RC Jr, Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Onoology. J Clin Oncol 2001; 19: 1865-1878.
4. Bell R, Verma S, Untch M et al. Maximizing clinical benefit with trastuzumab. Semin Oncol 2004; 31 (Suppl 10): 35-44.
5. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
7. Gregory RK, Smith IE. Vinorelbine - a clinical review. Br J Cancer 2000; 82: 1907-1913.
8. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-749.
9. Minotti G, Menna P, Salvatorelli E et al. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiatoxicity. Pharmacol Rev 2004; 56: 185-229.
10. Untch M, Eldtmann H, du Bois A et al, Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: Results of a phase I trial. Eur J Cancer 2004; 40: 988-997.
11. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322-329.
12. Kaufman PA, Schwartz G, Dragnev K et al. Phase I trial of Herceptin and Navelbine for patients with HER-2/neu (+) advanced breast cancer. Poster 431 presented at the 25th San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 11-14 December 2002.
13. Chan A, Martin M, Untch M et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: An international phase II trial. Br J Cancer 2006; 95: 788-793.
14. Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889-2895.
15. Bayo-Calero JL, Mayordomo-Cámara JI, Sánchez-Rovira P et al. A multicenter study with trastuzumab and vinorelbine as first and 2nd line treatment in patients (pats) with Her2 positive metastatic breast cancer (MBC). Breast Cancer Res Treat 2004; 82 (Suppl 1) (Abstr 5069).
16. Bernardo G, Palumbo R, Bernardo A et al. Final results of phase II study of weekly trastuzumab and vinorelbine in chemonaive patents with HER2-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 23: 59 (Abstr 731).
17. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730.
18. + metastatic breast cancer. Oncologist 2002; 7: 410-417.
19. Papaldo P, Fabi A, Ferretti G el al. A phase II study on metastatic breast cancer patents treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: Changing the natural history of HER2-positive disease. Ann Oncol 2006; 17: 630-636.
20. Lal A, Alidina A. Interim analysis of a phase II study of biochemotherapy in metastatic breast cancer (MBC). Eur J Cancer 2005; 3 (Suppl): 131 (Abstr 470).
21. de Wit M, Becker K, Thomssen C et al. Vinorelbine and trastuzumab as first line therapy in patents with HER2-positive metastatic breast cancer - interim analysis of a prospective, open-label, multicentre phase II trial. Ann Oncol 2004; 15 (Suppl 3): 37 (Abstr 138P).
22. Franquesa RM, Centelles M, Villadiego K et al. A multicenter study of trastuzumab (H) and vinorelbine (N) as first and second line therapy for patients (pts) with HER2-positive metastatic breast cancer (HER2+ MBC). J Clin Oncol 2005: 23: 94s (Abstr 868).
23. De Maio E, Pacilio C, Gravina A et al. A single-centre phase 2 study of vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer. Ann Oncol 2004; 15 (Suppl 3): 37 (Abstr 139P).
24. Bartsch R, Wenzel C, Pluschnig U et al. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: Results from a pilot trial. Cancer Chemother Pharmacol 2005; 57: 554-558.
25. Burstein HJ, Keshaviah A, Baron A et al. Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. J Clin Oncol 2006; 24: 40s (Abstr 650).
26. Chan A, Tubiana N, Ganju V et al. Optimal tolerance of an all-oral combination chemotherapy (CT) of oral vinorelbine (NVBo), capecitabine (C) with/without trastuzumab (T) in metastatic breast cancer (MBC) patients (pts): Safety results of two international multicenter studies. J Clin Oncol (Meeting Abstracts) 2006; 24: 576s (Abstr 10607) http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=40&abstractID=31846.
27. Baselga J. Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials. Oncology 2001; 61 (Suppl 2): 14-21.
28. Yardley DA, Greco FA, Porter LL et al. First line treatment with weekly docetaxel, vinorelbine, and trashizumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2004; 23: 37 (Abstr 643).
29. Jahanzeb M, Brufsky A, Erban J et al. Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. J Clin Oncol 2005; 23: 26s (Abstr 591).
30. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.